IP Verse

Method For Purifying Antibodies - EP3172220

The patent EP3172220 was granted to The United States OF America on Dec 27, 2023. The application was originally filed on Jul 27, 2015 under application number EP15750191A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3172220

THE UNITED STATES OF AMERICA
Application Number
EP15750191A
Filing Date
Jul 27, 2015
Status
Patent Maintained As Amended
Nov 24, 2023
Publication Date
Dec 27, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

RENTSCHLER BIOPHARMAApr 8, 2021VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE
EUSA PHARMA UKApr 7, 2021POTTER CLARKSONADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO0182958
INTERNATIONAL-SEARCH-REPORTWO2009016651
OPPOSITIONUS2002146388
OPPOSITIONWO2010141039
OPPOSITIONWO2013060867
OPPOSITIONWO2013075849
OPPOSITIONWO2013189554

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Multimodal Chromatography Handbook", GE Healthcare Life Sciences, (20131100), pages 1 - 115, XP055797469
OPPOSITION- Anonymous, "Storing purified antibodies", Antibodies: A Laboratory Manual, (19880000), page 287, XP055797513
OPPOSITION- "Captoâ„¢ adhere", GE Healthacare life sciences, (2012), pages 1 - 40, XP055797604
OPPOSITION- Klimyuk Victor, Gregory Pogue, Stefan Herz, John Butler, Hugh Haydon, "Production of Recombinant Andrens and Antibodies in Nicotiana befithamiana using Magnifection TechnoIogy : GMP-Compliant Facilities for Small- and Large-Scale Manudacturing", Current Topics in Microbiology and Immunology, (20120415), vol. 375, pages 127 - 154, XP055797479
OPPOSITION- Li Bohua, Hao Wang,Jianxin Dai, Junjie Ji, Weizhu Qian, Dapeng Zhang, Sheng Hou, Yajun Guo, "The difference of breakthrough discoveries on your terms", Immunology, (20050000), vol. 116, pages 487 - 498, XP055797507
OPPOSITION- Mohamed Al-Rubeai, "Cell Engineering (passage)", Antibody Expression and Production, (2011), XP055748424
OPPOSITION- "Multimodal Chromatography Handbook", GE Multimodal Chromatography Handbook, (20130000), XP055797469
OPPOSITION- Rowe Raymond C., Paul J. Sheskey, Marian E. Quinn, "Handbook of Pharmaceutical Excipients Sixth edition", Pharmaceutical Press, (20090000), pages 1 - 6, XP055797468
OPPOSITION- SCHWARTZ, "Diafiltration for Desalting or Buffer Exchange", BioProcess International, (20030500), pages 43 - 49, XP055453648
OPPOSITION- Schwartz Larry, "Diafiltration for Desalting or Buffer Exchange", BioProcess International, (20030500), pages 43 - 49, XP055453648
OPPOSITION- SCOPES ROBERT K, "Proteine Purification, principles and practise"", Proteine Purification, principles and practise", (1993), pages 349 - 352, XP055797473
OPPOSITION- Scopes Robert K., "Proteine Purification, principles and practise", Springer Verlag, (19930000), pages 349 - 352, XP055797473
OPPOSITION- SOMAN et al., "Analytical characterization of chi 4.18 A mouse-human chimeric disialoganglioside-specifictherapeutic antibody", mAbs, (20120000), vol. 4, no. 1, pages 84 - 100, XP055797465
OPPOSITION- Soman Gopalan, Abraham T. Kallarakal, Dennis Michiel, Xiaoyi Yang, Nimala Saptharishi, Hengguang Jiang, Steve Giardina, John Gilly, George Mitra, "Analytical characterization of chi 4.18 A mouse-human chimeric disialoganglioside-specifictherapeutic antibody", mAbs, (20120200), vol. 4, no. 1, pages 84 - 100, XP055797465
OPPOSITION- Van Reis R., A. Zydney, "Bioprocess membrane technology", ScienceDirect journal of MEMBRANE SCIENCE, (20070301), vol. 297, no. 16-50, pages 1 - 35, XP055797461
OPPOSITION- Nicholas W. Warne, "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", European Journal of Pharmaceutics and Biopharmaceutics, (20110601), vol. 78, pages 208 - 212, XP055534222
OPPOSITION- Horenstein Alberto L., Federico Crivellin, Ada Funaro, Marcela Said, Fabio Malavasi, "Design and scaleup of downstream processing of monoclonal antibodies for cancer therapy: from research to clinical proof of principle", Journal of Immunological Methods, (20030401), vol. 275, no. 1-2, pages 99 - 112, XP004416758
OPPOSITION- Gillies Stephen D., "A new platform for constructing antibody-cytokinefusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity", Protein Engineering, Design & Selection, (20130910), vol. 26, no. 10, pages 561 - 569, XP055640110
OPPOSITION- GILLIES STEPHEN D, "A new platform for constructing antibody-cytokinefusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity", PROTEIN ENGINEERING, DESIGN & SELECTION,, (20130910), vol. 26, no. 10, pages 561 - 569, XP055640110
OPPOSITION- GOSWAMI et al., "Developments and Challenges for mAb-Based Therapeutics", Antibodies, (20130000), vol. 2, pages 452 - 500, XP055128980
OPPOSITION- LIU et al., "Recovery and purification process development for monoclonal antibody production", mAbs, (20100000), vol. 2, no. 5, pages 480 - 499, XP002691388

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents